Poster: MDS-335: Ivosidenib (IVO) in Patients with IDH1-Mutant Relapsed/Refractory Myelodysplastic Syndrome (R/R MDS): Updated Enrollment for the MDS Sub-Study
Year: 2021
Type: article
Authors: Courtney D DiNardo, James M Foran, Justin M Watts, Eytan M Stein, Stéphane De Botton, Amir T Fathi, Gabrielle T Prince, Anthony S Stein, Richard M Stone, Prapti A Patel, Gail J Roboz, Martha L Arellano, Harry P Erba, Arnaud Pigneux, Robert K Stuart, Xavier Thomas, Geoffrey L Uy, Ian R Lemieux, Vickie Zhang, Stephanie M Kapsalis, Guillermo Garcia-Manero, David A Sallman
Institutions: The University of Texas MD Anderson Cancer Center, Mayo Clinic, Mayo Clinic in Florida, University of Miami, Sylvester Comprehensive Cancer Center, Memorial Sloan Kettering Cancer Center, Institut Gustave Roussy, Harvard University, Massachusetts General Hospital, Johns Hopkins Hospital, City Of Hope National Medical Center, Dana-Farber Cancer Institute, The University of Texas Southwestern Medical Center, NewYork–Presbyterian Hospital, Weill Cornell Medicine, Emory University, Winship Cancer Institute, Duke University, Centre Hospitalier Universitaire de Bordeaux, Medical University of South Carolina, Hôpital Lyon Sud, Washington University in St. Louis, Moffitt Cancer Center
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4200501228